VIATRIS INCVV

VIATRIS INC

209.00MXND
−13.12−5.91%
Last update at Feb 11, 16:25 GMT
MXN
No trades
See on Supercharts

VTRS fundamentals

Key facts

Market capitalization‪278.56 B‬MXN
Basic EPS (TTM)−14.53MXN
Founded2019
Employees (FY)‪38 K‬
CEOScott Andrew Smith
About

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Ownership
‪‪1.19 B‬‬
Free Float shares
‪‪1.16 B‬‬ (97.55%)
Closely held shares
‪‪29.29 M‬‬ (2.45%)
Free Float shares
‪‪1.16 B‬‬ (97.55%)
Closely held shares
‪‪29.29 M‬‬ (2.45%)
Capital structure
Market cap
‪‪278.56 B‬‬
Debt
‪‪315.70 B‬‬
Cash & equivalents
‪‪38.92 B‬‬
Enterprise value
‪‪555.34 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪278.56 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
0.87x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
0.87x
Valuation ratios
‪0.00‬
‪0.25‬
‪0.50‬
‪0.75‬
‪1.00‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪70.00‬
‪140.00‬
‪210.00‬
‪280.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−27%‬
‪−18%‬
‪−9%‬
‪0%‬
‪9%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−25.00 B‬‬
‪0.00‬
‪‪25.00 B‬‬
‪‪50.00 B‬‬
‪‪75.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Brands
Generics
By country
Period: 2023
Developed Markets
United States
Emerging Markets
China
Japan, Australia and New Zealand
Greater China

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Actual
Estimate
Earnings
Next:Feb 27, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪4.00‬
‪8.00‬
‪12.00‬
‪16.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
−64.97%
Payout ratio (TTM)
Dividend yield TTM
4.21%
Last payment
2.455
Last ex-date
Nov 22, 2024
Dividend history
‪0.0%‬
‪1.2%‬
‪2.4%‬
‪3.6%‬
‪4.8%‬
2019
2020
2021
2022
2023
‪0.00‬
‪2.50‬
‪5.00‬
‪7.50‬
‪10.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪90.00 B‬‬
‪‪180.00 B‬‬
‪‪270.00 B‬‬
‪‪360.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪170.00 B‬‬
‪‪340.00 B‬‬
‪‪510.00 B‬‬
‪‪680.00 B‬‬
Assets
Liabilities